Lead Product(s) : Aumolertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results of the study demonstrate the superior safety and efficacy profile of Ameile (aumolertinib) in the first-line treatment of EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC.
Brand Name : Ameile
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 31, 2022
Lead Product(s) : Aumolertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?